Cutaneous Langerhans cell histiocytosis in children under one year

Pediatr Blood Cancer. 2006 Jan;46(1):66-71. doi: 10.1002/pbc.20479.

Abstract

Background: To evaluate the clinical course and outcome of infants with Langerhans cell histiocytosis (LCH) involving skin and to estimate the incidence of progression to multi-system (M-S) disease in those with isolated skin involvement.

Methods: A retrospective review was conducted on 22 LCH patients who were younger than 12 months at the onset of their skin eruption.

Results: Twelve patients had isolated skin involvement at diagnosis and 10 were evaluable for progression. Four of the 10 (40%) evaluable patients progressed to multi-system (M-S) disease. Of the 10 patients with M-S disease at diagnosis, 5 had a history of a preceding skin eruption 2 to 13 months prior to diagnosis. Eleven of the 14 (79%) patients with M-S disease had risk organ involvement. The mortality rate of M-S disease was 50%.

Conclusions: It is important for primary caregivers to recognize that isolated cutaneous LCH in infants is not always a benign disorder. The diagnosis of self-healing cutaneous LCH should only be made in retrospect. Careful, albeit non-invasive, follow-up is recommended to monitor for disease progression and development of long-term complications.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Disease Progression
  • Female
  • Histiocytosis, Langerhans-Cell* / drug therapy
  • Histiocytosis, Langerhans-Cell* / mortality
  • Histiocytosis, Langerhans-Cell* / pathology
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Ontario / epidemiology
  • Retrospective Studies
  • Skin Diseases* / drug therapy
  • Skin Diseases* / mortality
  • Skin Diseases* / pathology
  • Survival Rate